(Q44550733)

4 December 2017

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

4 December 2017

1 reference

16

Rachakonda Prabhu

0 references

Elliot S. Barnathan

21

object named as

Elliot S Barnathan

1 reference

4 December 2017

Stephen I Rennard

1

1 reference

4 December 2017

Charles Fogarty

2

1 reference

4 December 2017

Steven Kelsen

3

1 reference

4 December 2017

William Long

4

1 reference

4 December 2017

Joe Ramsdell

5

1 reference

4 December 2017

James Allison

6

1 reference

4 December 2017

Donald Mahler

7

1 reference

4 December 2017

Constantine Saadeh

8

1 reference

4 December 2017

Thomas Siler

9

1 reference

4 December 2017

Phillip Snell

10

1 reference

4 December 2017

Phillip Korenblat

11

1 reference

4 December 2017

William Smith

12

1 reference

4 December 2017

Mitchell Kaye

13

1 reference

4 December 2017

Michael Mandel

14

1 reference

4 December 2017

Charles Andrews

15

1 reference

4 December 2017

James F Donohue

17

1 reference

4 December 2017

Rosemary Watt

18

1 reference

4 December 2017

Kim Hung Lo

19

1 reference

4 December 2017

Rozsa Schlenker-Herceg

20

1 reference

4 December 2017

John Murray

22

1 reference

4 December 2017

COPD Investigators

23

1 reference

4 December 2017

language of work or name

English

0 references

publication date

8 February 2007

1 reference

American Journal of Respiratory and Critical Care Medicine

4 December 2017

1 reference

4 December 2017

175

1 reference

4 December 2017

926-934

1 reference

4 December 2017

9

1 reference

Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training.

4 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Apoptosis of peripheral blood neutrophils in COPD exacerbation does not correlate with serum cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Tumor necrosis factor or tumor promoting factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Cytokines, apoptosis and cachexia: the potential for TNF antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Cellular and structural bases of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

COPD: current therapeutic interventions and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

A measure of quality of life for clinical trials in chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Standardization of Spirometry, 1994 Update. American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

First study of infliximab treatment in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

Pulmonary rehabilitation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200607-995OC

10.1164/RCCM.200607-995OC

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference